CRISPR Therapeutics
CRSP
CRSP
469 hedge funds and large institutions have $3.5B invested in CRISPR Therapeutics in 2023 Q4 according to their latest regulatory filings, with 120 funds opening new positions, 133 increasing their positions, 124 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
469
Holders Change
+66
Holders Change %
+16.38%
% of All Funds
6.88%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
120
Increased
133
Reduced
124
Closed
45
Calls
$304M
Puts
$301M
Net Calls
+$3.03M
Net Calls Change
+$14M
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
$534M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
$45.5M |
| 3 |
Morgan Stanley
New York
|
$51.7M |
| 4 |
Jane Street
New York
|
$29.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
$17.1M |
